Chronic Myelogenous Leukemia

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib	FDA
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib	FDA
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib	HC
Sensitivity (+)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib	HC